Tau seeds from patients induce progressive supranuclear palsy pathology and symptoms in primates
Brain · 01.06.2023 · 146 (6) · 2524-2534
DOI: 10.1093/brain/awac428 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 16.11.2022. Verfasst von Morgane Darricau und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of Bordeaux, CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France. Hauptthemen laut MEDLINE: Supranuclear Palsy, Progressive, Neurodegenerative Diseases, Tauopathies. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust, PSP-France Foundation, Bettencourt-Schueller Foundation.
Abstract (Originalsprache)
Progressive supranuclear palsy is a primary tauopathy affecting both neurons and glia and is responsible for both motor and cognitive symptoms. Recently, it has been suggested that progressive supranuclear palsy tauopathy may spread in the brain from cell to cell in a ‘prion-like’ manner. However, direct experimental evidence of this phenomenon, and its consequences on brain functions, is still lacking in primates. In this study, we first derived sarkosyl-insoluble tau fractions from post-mortem brains of patients with progressive supranuclear palsy. We also isolated the same fraction from age-matched control brains. Compared to control extracts, the in vitro characterization of progressive supranuclear palsy-tau fractions demonstrated a high seeding activity in P301S-tau expressing cells, displaying after incubation abnormally phosphorylated (AT8- and AT100-positivity), misfolded, filamentous (pentameric formyl thiophene acetic acid positive) and sarkosyl-insoluble tau. We bilaterally injected two male rhesus macaques in the supranigral area with this fraction of progressive supranuclear palsy-tau proteopathic seeds, and two other macaques with the control fraction. The quantitative analysis of kinematic features revealed that progressive supranuclear palsy-tau injected macaques exhibited symptoms suggestive of parkinsonism as early as 6 months after injection, remaining present until euthanasia at 18 months. An object retrieval task showed the progressive appearance of a significant dysexecutive syndrome in progressive supranuclear palsy-tau injected macaques compared to controls. We found AT8-positive staining and 4R-tau inclusions only in progressive supranuclear palsy-tau injected macaques. Characteristic pathological hallmarks of progressive supranuclear palsy, including globose and neurofibrillary tangles, tufted astrocytes and coiled bodies, were found close to the injection sites but also in connected brain regions that are known to be affected in progressive supranuclear palsy (striatum, pallidum, thalamus). Interestingly, while glial AT8-positive lesions were the most frequent near the injection site, we found mainly neuronal inclusions in the remote brain area, consistent with a neuronal transsynaptic spreading of the disease. Our results demonstrate that progressive supranuclear palsy patient-derived tau aggregates can induce motor and behavioural impairments in non-human primates related to the prion-like seeding and spreading of typical pathological progressive supranuclear palsy lesions. This pilot study paves the way for supporting progressive supranuclear palsy-tau injected macaque as a relevant animal model to accelerate drug development targeting this rare and fatal neurodegenerative disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Bordeaux, CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.
- UK Dementia Research Institute, Department of Clinical Neurosciences, University of Cambridge, CB2 0AH Cambridge, UK.
- Swiss Federal Institute of Technology (EPFL), CH-1011 Lausanne, Switzerland.
- Defitech Center for Interventional Neurotherapies (NeuroRestore), CH-1011 Lausanne, Switzerland.
- Centre Hospitalier Universitaire Vaudois (CHUV), CH-1011 Lausanne, Switzerland.
- Motac Neuroscience, F-33000 Bordeaux, France.
ORCID-Profile: Grégoire Courtine, Benjamin Dehay, Erwan Bezard, Vincent Planche
Förderung
- Wellcome Trust
- PSP-France Foundation
- Bettencourt-Schueller Foundation
- GPR BRAIN_2030
- Ministère de l’Enseignement Supérieur et de la Recherche
- Innovative Medicines Initiative 2 Joint
- European Union’s Horizon 2020 research and innovation program and EFPIA
- Sir Henry Dale Fellowship
Zitieren
APA
Darricau, M., Katsinelos, T., Raschella, F., Milekovic, T., Crochemore, L., Li, Q., Courtine, G., McEwan, W. A., Dehay, B., Bezard, E., & Planche, V. (2023). Tau seeds from patients induce progressive supranuclear palsy pathology and symptoms in primates. Brain, 146(6), 2524-2534. https://doi.org/10.1093/brain/awac428
Vancouver
Darricau M, Katsinelos T, Raschella F, Milekovic T, Crochemore L, Li Q, et al. Tau seeds from patients induce progressive supranuclear palsy pathology and symptoms in primates. Brain. 2023;146(6):2524-2534. doi:10.1093/brain/awac428
BibTeX
@article{Darricau2023,
author = {Darricau, Morgane and Katsinelos, Taxiarchis and Raschella, Flavio and Milekovic, Tomislav and Crochemore, Louis and Li, Qin and Courtine, Grégoire and McEwan, William A and Dehay, Benjamin and Bezard, Erwan and Planche, Vincent},
title = {Tau seeds from patients induce progressive supranuclear palsy pathology and symptoms in primates},
journal = {Brain},
year = {2023},
volume = {146},
number = {6},
pages = {2524--2534},
doi = {10.1093/brain/awac428}
}
EUVIMED